NewStem

Company Overview

Snapshot

Founded in September 2016, NewStem operates with 1–10 employees and has raised $5 million across three funding rounds from NovelStem International Corp and Illumina Accelerator. The company filed FDA Pre-Submission and EMA IVDD for a diagnostic device in April 2022.

Business overview

NewStem is a Health Tech & Life Sciences company focused on precision medicine therapeutics. The company develops a novel technology for predicting resistance to anticancer treatments, creating a diagnostic tool based on pioneering research in human haploid pluripotent stem cells (HHPSCs). This technology enables the generation of fully functional stem cells with a single copy of each gene, forming a unique library of HHPSCs with various mutations and genetic makeups. NewStem's diagnostic tools are designed for personalized medicine, serving the oncology and diagnostics markets.

Strategic signal

In September 2022, Illumina Accelerator invested in NewStem as part of its third global cycle for genomics startups. This investment signals strong validation of NewStem's innovative approach to genomics and its potential to impact the precision medicine landscape, particularly in developing diagnostic tools for cancer treatment resistance.

Company Intelligence Q&A

When did NewStem file for FDA and EMA regulatory submissions?

In April 2022, NewStem filed FDA Pre-Submission and EMA IVDD (In Vitro Diagnostic Regulation) for its diagnostic device, aiming to advance its revolutionary treatment-changing technology.

Which accelerator program did NewStem participate in?

In September 2022, NewStem was part of the Illumina Accelerator's third global cycle, which invests in genomics startups.

What is the primary application of NewStem's diagnostic tool?

NewStem's diagnostic tool is designed to predict resistance to anticancer treatments, enabling personalized medicine by assessing the influence of mutated genes on drug responses.